Assessment of Decision Tool to Select Women for Gynecologic Sparing Radical Cystectomy (NCT06184516)
π©Ί Plain-English Summary (8th-Grade Level)
Currently, the standard of care for female patients undergoing radical cystectomy includes the removal of the bladder, pelvic lymph nodes, anterior vagina, uterus, fallopian tubes and ovaries. Removal of female ancillary organs, both in pre and post-menopausal stages is associated with reduction in various quality of life metrics, including sexual health, cognitive decline and depression. Furthermore, removal of ovaries has been associated with increased cardiovascular events, metabolic acidosis, osteoporosis and bone fractures. In premenopausal women, the removal of the ovaries is associated with increased all-cause mortality. From an oncologic standpoint, multi institutional retrospective reviews have demonstrated certain pre-operative radiographic and cystoscopic risk factors that are associated with bladder cancer involvement of female reproductive organs. The absence of these unfavorable risk factors may provide an opportunity to spare women from undergoing unnecessary reproductive organ removal during RC. In doing so, this may eliminate the associated sequelae of removing these additional organs while also providing acceptable oncologic care. The investigators thus propose a decision tool to stratify women undergoing radical cystectomy as favorable and unfavorable for reproductive organ sparing radical cystectomy. This decision tool classification will be used to decide which patients will undergo reproductive organ sparing radical cystectomy versus radical cystectomy in this study.
Who can join: Review the eligibility criteria below.
Location: University of Florida β Gainesville, Florida
Age range: 18 Years to 99 Years
π§ͺ Interventions in This Study
- Reproductive organ sparing radical cystectomy (PROCEDURE)
- Radical cystectomy (PROCEDURE)
π "Do I Qualify?" β 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria β
π All Participating Trial Locations (1 Sites)
- University of Florida β Gainesville, Florida
π Contact the Study Coordinator
Phone: (352) 273-6913
Email: ndavilatorres@ufl.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
π° Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA Β§ 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urothelial Carcinoma Bladder
- Intravesical Gemcitabine and Docetaxel for BCG naΓ―ve Non-muscle Invasive Bladder Cancer β Baltimore, Maryland
- Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer β Houston, Texas
- A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors β Duarte, California
- Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer β Philadelphia, Pennsylvania
Explore by condition: All Urothelial Carcinoma Bladder clinical trials
π‘ How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.